Pharma and biopharma regulatory outsourcing
Pharmaceutical and biotechnology vendors buying outsourced regulatory submissions, regulatory consulting, writing and publishing, product registration and related approval support
Intelligence / Healthtech & medtech market map / Clinical and regulatory support services / Regulatory affairs and submissions services
Advice, documentation, testing and submission support for regulatory approval and market authorisation across jurisdictions, including quality-system and technical-file preparation.
Split by customer type.
Pharmaceutical and biotechnology vendors buying outsourced regulatory submissions, regulatory consulting, writing and publishing, product registration and related approval support
Medical-device and diagnostic vendors outsourcing regulatory-affairs advice, documentation, testing coordination and submission support for product approval and market authorisatio
Digital-health and SaMD vendors buying regulatory advice, software documentation, quality-system support and submission preparation for software and AI-enabled products.
Life-science tools, laboratory and in-vitro diagnostic vendors buying regulatory advice, technical-file preparation, testing support and submission services for approval and market
$3.2B ($2.1B–$4.6B) · 2025 · Triangulated
Device regulatory affairs outsourcing is USD 2.1B in 2024 rising to USD 8.1B by 2031 at 6-7% [2]; the broader regulatory affairs outsourcing market is USD 8.1B (2025) to USD 15.7B (2034) at 7.6% [9], USD 8.20B (2025) [6], USD 8.40B (2025) [5], USD 8.95B (2025) [10]. Regulatory consulting is the largest service type at 40% of the outsourcing market [8]. Medtech/diagnostics share of the broader market is taken at roughly 35-40% (device segment USD 2.1B [2] plus diagnostics and digital-health vendors), giving a USD 2.1-4.6B range and a USD 3.2B midpoint for 2025. Forecast anchored on the USD 8.1B 2031 device figure [2].
// Sell into Regulatory affairs and submissions services